Last reviewed · How we verify
BAY 94-8862
BAY 94-8862 is a monoclonal antibody targeting SARS-CoV-2.
BAY 94-8862 is a monoclonal antibody targeting SARS-CoV-2. Used for Prevention of COVID-19.
At a glance
| Generic name | BAY 94-8862 |
|---|---|
| Sponsor | Bayer |
| Drug class | Monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 2 |
Mechanism of action
BAY 94-8862 is a human monoclonal antibody that targets the SARS-CoV-2 spike protein, preventing the virus from entering host cells. It is designed to neutralize the virus and prevent infection.
Approved indications
- Prevention of COVID-19
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
- A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction (PHASE3)
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction (PHASE3)
- An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
- An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
- An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY 94-8862 CI brief — competitive landscape report
- BAY 94-8862 updates RSS · CI watch RSS
- Bayer portfolio CI